leadf
logo-loader
viewTiziana Life Sciences PLC

Full interview: Tiziana Life Sciences CEO explains how its potential coronavirus fighting antibody is unique

Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) CEO and Chief Scientific Officer Dr Kunwar Shailubhai tells Proactive the US and UK-based biotechnology company has developed an antibody that holds 'distinct advantages' over biotech giants Sanofi and Roche's drugs.

Dr Shailubhai says dual mechanism of action to inhibit signalling by the membrane-bound and soluble IL-6 receptors along with the rapid depletion of circulating IL-6 cytokine make its antibody unique. The company recently raised gross proceeds of approximately $10 million to help fund development efforts.

Quick facts: Tiziana Life Sciences PLC

Price: 152 GBX

AIM:TILS
Market: AIM
Market Cap: £295.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Happy new year, happy new vaccine as AstraZeneca/Oxford...

FTSE 100 opened with a jump in the first trading day of the new year although coronavirus infections continue to surge. London’s main index added 120 points to 6,580 in early trading. The UK has begun the rollout of the COVID-19 vaccine produced by AstraZeneca PLC (LON:AZN) and Oxford...

2 weeks ago

2 min read